p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug

Nature Cell Biology

Volumn 11, Issue 6, 2009, Pages 694-704

  Wang, Shu Ping ^a   Wang, Wen Lung ^a   Chang, Yih Leong ^b   Wu, Chen Tu ^b   Chao, Yu Chih ^a   Kao, Shih Han ^c   Yuan, Ang ^d   Lin, Chung Wu ^d   Yang, Shuenn Chen ^e   Chan, Wing Kai ^d   Li, Ker Chau ^f   Hong, Tse Ming ^g   Yang, Pan Chyr ^c,d,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR SLUG; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER CONTROL; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE; UBIQUITINATION; WILD TYPE;

ANIMALS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349166210     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1875     Document Type: Article

References (46)

1. Steeg, P. S. Tumor metastasis: Mechanistic insights and clinical challenges. Nature Med. 12, 895-904 (2006).
2. Michael, D. & Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13, 49-58 (2003).
3. Vousden, K. H. & Lane, D. P. p53 in health and disease. Nature Rev. Mol. Cell Biol. 8, 275-283 (2007).
4. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
5. Soussi, T. & Beroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev. Cancer 1, 233-240 (2001).
6. Yuan, A. et al. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J. Clin. Oncol. 20, 900-910 (2002).
7. Bukholm, I. K., Nesland, J. M., Karesen, R., Jacobsen, U. & Borresen-Dale, A. L. Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch. 431, 317-321 (1997).
8. Hsiao, M. et al. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145, 702-714 (1994).
9. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872 (2004).
10. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
11. Mehta, S. A. et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: Implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene 26, 3329-3337 (2007).
12. Chen, Y. W. et al. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res. 67, 7589-7596 (2007).
13. Okawa, T. et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 21, 2788-2803 (2007).
14. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Rev. Mol. Cell Biol. 7, 131-142 (2006).
15. Mareel, M. & Leroy, A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 83, 337-376 (2003).
16. Bremnes, R. M. et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J. Clin. Oncol. 20, 2417-2428 (2002).
17. Frixen, U. H. et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 113, 173-185 (1991).
18. Handschuh, G. et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 18, 4301-4312 (1999).
19. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H. & Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392, 190-193 (1998).
20. Hajra, K. M., Ji, X. & Fearon, E. R. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18, 7274-7279 (1999).
21. Hennig, G. et al. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 11, 475-484 (1995).
22. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nature Rev. Mol. Cell Biol. 3, 155-166 (2002).
23. Bolos, V. et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 116 499-511 (2003).
24. Hajra, K. M., Chen, D. Y. & Fearon, E. R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62, 1613-1618 (2002).
25. Shih, J. Y. et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin. Cancer Res. 11, 8070-8078 (2005).
26. Castro, A. C. et al. Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J. Pathol. 211, 507-515 (2007).
27. Shioiri, M. et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br. J. Cancer 94, 1816-1822 (2006).
28. Martin, T. A., Goyal, A., Watkins, G. & Jiang, W. G. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 12, 488-496 (2005).
29. Uchikado, Y. et al. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 11, 1174-1180 (2005).
30. Gupta, P. B. et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nature Genet. 37, 1047-1054 (2005).
31. Aylon, Y. & Oren, M. Living with p53, dying of p53. Cell 130 597-600 (2007).
32. Manfredi, J. J. p53 and apoptosis: It's not just in the nucleus anymore. Mol. Cell 11, 552-554 (2003).
33. Kajita, M., McClinic, K. N. & Wade, P. A. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol. Cell Biol. 24, 7559-7566 (2004).
34. Lozano, G. The oncogenic roles of p53 mutants in mouse models. Curr. Opin. Genet. Dev. 17, 66-70 (2007).
35. Levrero, M. et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 113, 1661-1670 (2000).
36. Havrilesky, L. et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3814-3825 (2003).
37. Cano, A. et al. Expression pattern of the cell adhesion molecules. E-cadherin, P-cadherin and α6 β4 integrin is altered in pre-malignant skin tumors of p53-deficient mice. Int. J. Cancer 65, 254-262 (1996).
38. Lewis, B. C. et al. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol. Cell Biol. 25, 1228-1237 (2005).
39. Derksen, P. W. et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10, 437-449 (2006).
40. Bermejo-Rodriguez, C. et al. Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. Genomics 87, 113-118 (2006).
41. Wu, W. S. et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123, 641-653 (2005).
42. Harada, J. et al. Requirement of the co-repressor homeodomain-interacting protein kinase 2 for ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation. J. Biol. Chem. 278, 38998-39005 (2003).
43. Mountain, C. F. Revisions in the international system for staging lung cancer. Chest 111, 1710-1717 (1997).
44. Travis, W., Brambilla, E., Muller-Hermelink, H. K. & Harris, C. C. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart (IARC Press, 2004).
45. Chang, Y. L. et al. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin. Cancer Res. 13, 52-58 (2007).
46. Chu, Y. W. et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 17, 353-360 (1997).